Connect with us
The Spanish multinational Grifols, specialized in the production of blood products, has continued to expand its network with the launch of the first integrated plasma supply...
In September, Grifols agreed to acquire the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG for $1.3 billion (€1.1 billion), which holds 90% of the...
The bond proceeds will be used to finance the $1.3 billion (€1.1 billion) purchase of the entire share capital of Tiancheng Pharmaceutical Holdings, which in turn...
The performance of the pharmaceutical sector in the third quarter was worse than that of the Ibex35, the Spanish benchmark index, which fell by 0.3% in...
Grifols has assured that 87.93% of bondholders of its secured bonds, 81.01% of unsecured bonds, the required 93.82% of underwriters of its syndicated credit facility, and...
Grifols increases its profits in the first six months of the year. The Spanish multinational, which specializes in the production of plasma derivatives, achieved a profit...
The total economic impact of Grifols in the main countries where it operates is estimated at $8.85 billion (€7.5 billion) and 140,000 jobs generated, including direct,...
This past year was not a good one for the Spanish pharmaceutical sector. According to a calculation, the six listed companies on the continuous market has...
Grifols' gross operating profit (Ebitda) was $356.4 million (€296.8 million) compared to $421 million (€351 million) in the first quarter of 2020 and accounted for 25.1%...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...